ANCN:NSD-Anchiano Therapeutics Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.05

Change

+0.04 (+3.47)%

Market Cap

USD 7.49M

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Cambridge, Massachusetts.

Company Website : http://www.anchiano.com

Address : One Kendall Square, Cambridge, MA, United States, 02139

Employees : 16

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.75

52 Week High : 2.49

Short Ratio : 0.18

52 Week Low : 0.56

Shorted Shares : 11,402

200 Day Moving Average : 1.02

Shorted Shares Previous Month : 8,393

50 Day Moving Average : 1.03

Shares Held By Insiders : 189.73%

Shares Held by Institutions : 27.81%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.45 (-0.17%)

 USD69.85B 33.27 26.59
REGN Regeneron Pharmaceuticals, Inc

-2.14 (-0.37%)

 USD61.08B 21.61 16.69
SGEN Seattle Genetics, Inc

+5.56 (+3.01%)

 USD32.18B N/A N/A
MRNA Moderna, Inc

+1.08 (+1.55%)

 USD27.41B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

-1.13 (-0.99%)

 USD25.08B 29.87 27.00
BGNE BeiGene, Ltd

-1.75 (-0.62%)

 USD24.87B N/A N/A
RPRX Royalty Pharma plc

+1.14 (+2.85%)

 USD24.33B 34.81 9.50
GMAB Genmab A/S

+0.93 (+2.58%)

 USD23.71B 25.56 2.87
IMMU Immunomedics, Inc

+0.16 (+0.19%)

 USD19.73B N/A N/A
INCY Incyte Corporation

+3.81 (+4.40%)

 USD18.93B 47.64 35.20

ETFs Containing ANCN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -25.36% 32% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.36% 32% F 31% F
Trailing 12 Months  
Capital Gain -54.55% 12% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -54.55% 12% F 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -28.58% N/A N/A 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -28.58% N/A N/A 5% F
Risk Return Profile  
Volatility (Standard Deviation) 37.39% N/A N/A 35% F
Risk Adjusted Return -76.44% N/A N/A 7% F
Market Capitalization 7.49M 2% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.92 96% A 76% C
Price / Cash Flow Ratio -0.46 12% F 60% D-
EV/EBITDA 0.05 86% B 98% A+
Management Effectiveness  
Return on Equity -119.78% 25% F 10% F
Return on Invested Capital -282.91% 5% F 2% F
Return on Assets -48.52% 18% F 6% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.08 96% A 96% A
Short Percent N/A N/A N/A N/A N/A
Beta 0.75 82% B- 73% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.